References relevant to drug promotion: 2000
This page lists all the 227 references relevant to drug promotion in the Healthy Skepticism library that were published in 2000.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL2631
Nuesch R, Dieterle T.
Industry-sponsored research.
Lancet 2000 Dec 23-30;356(9248):2193-4
Link to source with long URL
HSL2635
Halpern SD, Karlawish JH.
Industry-sponsored research. University of Pennsylvania Research Ethics Working Group.
Lancet 2000 Dec 23-30;356(9248):2193
Link to source with long URL
HSL3033
Neusch R.
Industry-sponsored research (2nd of two letters)
Lancet 2000 Dec 23-30;356:2193
HSL7575
Djulbegovic B, Bennett CL, Adams JR, Lyman GH.
Authors' reply
The Lancet 2000 Dec 23;356(9248):2193
HSL7576
Giannakakis IA, Ioannidis JP.
Arabian nights-1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report.
BMJ 2000 Dec 23-30;321(7276):1563-4
http://www.bmj.com/cgi/content/full/321/7276/1563
HSL273
Willman D.
How a New Policy Led to Seven Deadly Drugs
The Los Angeles Times 2000 Dec 20
HSL274
Willman D.
Case Studies: Drug After Drug,Warnings Ignored Propulsid: A Heartburn Drug, Now Linked to Children's Deaths Once evidence of harm emerged, FDA took years to withdraw approval.
The Los Angeles Times 2000 Dec 20
HSL275
Willman D.
RAXAR: Warning on Label Omits Deaths Heart problems were mentioned in fine print, but not key dosage data.
The Los Angeles Times 2000 Dec 20
HSL277
Willman D.
REDUX: Unheeded warnings on Lethal Diet Pill Heart damage causes billions of dollars in potential legal liability.
The Los Angeles Times 2000 Dec 20
HSL278
Willman D.
DURACT: Painkiller Posed Risk of Damage to Liver Drugmaker's lobbying won fine print instead of prominent warning.
The Los Angeles Times 2000 Dec 20
HSL279
Willman D.
POSICOR: 143 Sudden Deaths Did Not Stop Approval With study results kept secret, nation got another blood-pressure drug.
The Los Angeles Times 2000 Dec 20
HSL280
Willman D.
LOTRONEX: Officer Foresaw Deadly Effects "Irritable bowel" remedy pulled after reports of serious injuries.
The Los Angeles Times 2000 Dec 20
Link to source with long URL
HSL282
Willman D.
REZULIN: Fast-Track Approval and a Slow Withdrawal Diabetes drug stayed on the market a year after being listed among the most risky.
The Los Angeles Times 2000 Dec 20
HSL284
Willman D.
RELENZA: Official Asks If One Day Less of Flu Is Worth It Still on the market, the drug has been linked to 22 deaths so far.
The Los Angeles Times 2000 Dec 20
HSL8526
Walley T, Earl-Slater A, Haycox A, Bagust A.
An integrated national pharmaceutical policy for the United Kingdom?
BMJ 2000 Dec 16;321(7275):1523-6
http://www.bmj.com/cgi/content/full/321/7275/1523
HSL8541
Thompson CA.
Federal drug discount program proves tricky for hospitals to navigate
American Journal of Health System Pharmacy 2000 Dec 1;57:2130, 2134, 2139-2140
HSL336
Morgan S, Barer M, Evans R.
Health economists meet the fourth tempter: drug dependency and scientific discourse.
Health Econ 2000 Dec;9(8):659-67
http://www3.interscience.wiley.com/cgi-bin/abstract/76505087/ABSTRACT
HSL346
Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL.
Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
Ann Oncol 2000 Dec;11(12):1591-5
Nil
HSL359
Bell RA, Wilkes MS, Kravitz RL.
The educational value of consumer-targeted prescription drug print advertising.
J Fam Pract 2000 Dec;49(12):1092-8
Nil
HSL7574
[No authors listed]
Trial results must be accessible: Clinical research data, a public asset.
Prescrire Int. 2000 Dec;9(50):183
HSL8535
Richardson K, Basskin L.
Cost benefit analysis of methods used to access manufacturers' pharmaceutical assistance programs
ASHP Midyear Clinical Meeting 2000 Dec;35
HSL8550
Hailemeskel B, Gavgani MZ.
Assessment of accuracy and completeness of the prescription drug information on the Internet
ASHP Midyear Clinical Meeting 2000 Dec;35
HSL8551
Murray SG, Albano DL, Buttaro ML, Goldkamp AH.
Evaluation of health care professional satisfaction with a pharmaceutical industry's standard response letters and assessment of their impact on prescribing behavior
ASHP Midyear Clinical Meeting 2000 Dec;35
HSL8552
Schultz PT, Hogan TT, Clark KE.
Assessment of the impact of direct to consumer advertising of prescription drugs on consumers and prescribers
ASHP Midyear Clinical Meeting 2000 Dec;35
HSL328
McCrary SV, Anderson CB, Jakovljevic J, Khan T, McCullough LB, Wray NP, Brody BA.
A national survey of policies on disclosure of conflicts of interest in biomedical research.
N Engl J Med 2000 Nov 30;343(22):1621-6
http://content.nejm.org/cgi/content/abstract/343/22/1621
HSL345
Lo B, Wolf LE, Berkeley A.
Conflict-of-interest policies for investigators in clinical trials.
N Engl J Med 2000 Nov 30;343(22):1616-20
http://content.nejm.org/cgi/content/abstract/343/22/1616
HSL3049
Martin JB, Kasper DL.
In whose best interest? Breaching the academic-industrial wall
New England Journal of Medicine 2000 November 30;343(22):1646-1649
http://content.nejm.org/cgi/content/extract/343/22/1646
HSL7573
Drazen JM, Koski G.
To protect those who serve.
N Engl J Med 2000 Nov 30;343(22):1643-5
http://content.nejm.org/cgi/content/extract/343/22/1643
HSL2986
Weber W.
Merck Sharp & Dohme prosecuted for pampering Dutch doctors
Lancet 2000 Nov 25;356:1832
HSL1659
Jureidini JN.
Epidemic of schizophrenia in children or inappropriate prescribing?
Med J Aust 2000 Nov 20;173(10):555-6
HSL3046
McCarthy M.
Company sought to block paper's publication
Lancet 2000 Nov 11;356:1659
HSL2992
Summers W, Driscoll J, Orient J.
The pharmaceutical industry - to whom is it accountable? (7th of 10 letters)
New England Journal of Medicine 2000 Nov 9;343(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2995
Schwarting J.
The pharmaceutical industry - to whom is it accountable? (3rd of 10 letters)
New England Journal of Medicine 2000 Nov 9;343(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2996
Schwarting JS.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1416
HSL3005
Rightor N.
The pharmaceutical industry - to whom is it accountable? (6th of 10 letters)
New England Journal of Medicine 2000 Nov 9;343(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL3013
Reif M.
The pharmaceutical industry - to whom is it accountable? (2nd of 10 letters)
New England Journal of Medicine 2000 Nov 9;343(19):1415-6
http://content.nejm.org/cgi/content/full/343/19/1415
HSL3042
Mehta DJ.
The pharmaceutical industry - to whom is it accountable? (9th of 10 letters)
New England Journal of Medicine 2000 Nov 9;343(19):1417
HSL7569
Bohrer RA.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL7570
Hayes TA.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL7571
Holmer AF.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1415
http://content.nejm.org/cgi/content/full/343/19/1415
HSL7572
Jacobs C.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9;343(19):1416-7
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2363
Biotech Firm Tries to Suppress Publication of Research: Academic Freedom at Heart of Issue
Journal of the American Medical Association 2000 Nov 1
HSL2173
Potdar RD.
Educating ourselves.
Indian Pediatr 2000 Nov;37(11):1287-8
http://www.indianpediatrics.net/nov2000/nov-1287-1288.htm
HSL4156
Rowsell LB.
Policy statement. Advertising campaigns of branded and unbranded messages.
: Therapeutic Products Directorate, Health Canada.; 2000 Nov
Link to source with long URL
HSL8527
Wechsler J.
FDA launches debate on renewing user fees and updating FDA Modernization Act
Formulary 2000 Nov;35:925-926
HSL8529
Pines WL.
Direct-to-consumer advertising.
Ann Pharmacother 2000 Nov;34(11):1341-4
http://www.theannals.com/cgi/reprint/34/11/1341
HSL7645
More U.S. Children Being Diagnosed With Youthful Tendency Disorder
The Onion 2000 Oct 27
HSL8447
Tieman J.
Just roiling along.
Mod Healthc 2000 Oct 23;30(44):8-9
HSL7568
Kiln MR, Hirst JMD.
Academia and industry
Lancet 2000 Oct 14;356:1359
HSL350
Freemantle N, Anderson IM, Young P.
Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.
Br J Psychiatry 2000 Oct;177:292-302
http://bjp.rcpsych.org/cgi/content/full/177/4/292
HSL2459
Norman GR.
The epistemology of clinical reasoning: perspectives from philosophy, psychology, and neuroscience.
Acad Med 2000 Oct;75(10)
Link to source with long URL
HSL2991
Susman E.
No such thing as a free lunch
Scrip Magazine 2000 October;94(19)
HSL3040
Mintzes B, Lippman A.
Re: Selling, or selling out? [response]
Journal of the Society of Obstetricians and Gynaecologists of Canada 2000 Oct;22(10):786-787
HSL5315
Bhatt AD.
Clinical trial publications.
Issues Med Ethics 2000 Oct-Dec;8(4):119-21
HSL6246
Kimanani E, Stypinski D, Curtis G, Stiles M, Heessels P, Logan S, Nelson K, St Germain E, Boswell G.
A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products.
J Clin Pharmacol 2000 Oct;40(10):1102-8
HSL7564
Baumgartner A.
Re: Selling, or selling out?
Journal of the Society of Obstetricians and Gynaecologists of Canada 2000 Oct;22(10):786
HSL7565
Feldman W.
The pharmaceutical industry/L'industrie pharmaceutique
Annales CRMCC 2000 Oct;33(7):404-405
HSL7566
Kravitz RL.
Direct-to-consumer advertising of prescription drugs.
West J Med 2000 Oct;173(4):221-2
Link to source with long URL
HSL7567
Davis JJ.
Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs
J Health Commun 2000 Oct;5(4):349-69
HSL8454
Challenges and opportunities in the Canadian drug industry
HealthCare Distributors 2000 Oct;52:18, 20-21
HSL353
de Barros JAC.
One more case of the double standard: discrepancies between drug information provided to Brazilian and American physicians
Pharmacoepidemiology and Drug Safety 2000;9:281-287
http://www3.interscience.wiley.com/cgi-bin/abstract/73501719/ABSTRACT
HSL2993
Sullivan P.
Freebies to MDs targeted as drug industry starts publicizing CME fines
Canadian Medical Association Journal 2000 Sep 19;163(6):749
HSL7563
Horton R.
The less acceptable face of bias.
Lancet 2000 Sep 16;356(9234):959-60
http://linkinghub.elsevier.com/retrieve/pii/S0140673600027112
HSL7561
Bruera E, Ripamonti C, Beattie-Palmer L.
Use of trade names of drugs in abstracts from pain congresses.
N Engl J Med 2000 Sep 14;343(11):818
HSL2362
Borger J.
Dirty rats leave Gore a subliminal message: It was only visible for a thirtieth of a second but here's proof the gloves are really off Special report: the US elections
The Guardian 2000 Sep 13
HSL8538
Kirkpatrick MA, Shadis ER.
Pharmacy connect-free drug program for community dwelling elders
Journal of the American Pharmaceutical Association 2000 Sep 10;40:672-674
HSL2175
Drug-company influence on medical education in USA
Lancet 2000 Sep 2;356(9232):781
http://linkinghub.elsevier.com/retrieve/pii/S0140673600026453
HSL3048
McCarthy M.
Conflict of interest taints vaccine approval process, charges US report.
Lancet 2000 Sep 2;356(9232):838
HSL3028
Wenger NS, Lieberman JR.
The orthopaedic surgeon and industry. Ethics and industry incentives.
Clinical Orthopaedics and Related Research 2000 September 01(378):39-43
Link to source with long URL
HSL360
Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF.
The value of pharmaceutical representative visits and medication samples in community-based family practices.
J Fam Pract 2000 Sep;49(9):811-6
Nil
HSL2998
Sams WM, Freedberg IM.
The dermatology-industry interface: defining the boundaries.
J Am Acad Dermatol 2000 Sep;43(3):550-4
Link to source with long URL
HSL4137
Findlay S.
Prescription Drugs and Mass Media Advertising.
Washington, DC: National Institute of Health Care Management.; 2000 Sep
HSL4141
Galbally R.
Review of drugs, poisons, and controlled substances legislation. Draft Final Report.
Canberra: Therapeutic Goods Administration,; 2000 Sep
HSL7560
Gifts: a transcript of a television report
MaLAM International News 2000 Sep-Oct;18(9-10):1-4
HSL8479
Thompson L.
User fees for faster drug reviews: are they helping or hurting the public health?
FDA Consumer 2000 Sep-Oct;34:25-29
HSL4164
Petersen M.
What’s black and white and sells medicine?
N Y Times 2000 Aug 27:12 [sect 3, p1].
HSL8534
Conlan MF.
Congress takes step to let RPhs import Rx drugs
Drug Topics 2000 Aug 21;144:61
HSL5098
Williams R.
Pharmaceutical Industry and the media
Radio National 2000 Aug 20
http://www.abc.net.au/rn/science/ockham/stories/s164976.htm
HSL352
Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH.
The uncertainty principle and industry-sponsored research.
Lancet 2000 Aug 19;356(9230):635-8
http://linkinghub.elsevier.com/retrieve/pii/S0140673600026052
HSL7559
Editorial .
Experimenting with direct-to-consumer advertising
The Lancet 2000 Aug 19;356:607
HSL8466
Pharmacists say no to DTC promotions
Chemist and Druggist 2000 Aug 19;254
HSL2982
Young S.
Is academic medicine for sale? (3rd of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):508-509
http://content.nejm.org/cgi/content/full/343/7/508
HSL3002
Ruane T.
Is academic medicine for sale? (10th of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL3004
Ross L.
Is academic medicine for sale? (1st of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):508
http://content.nejm.org/cgi/content/full/343/7/508
HSL3031
Norton JW.
Is academic medicine for sale? (2nd of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):508
http://content.nejm.org/cgi/content/full/343/7/508
HSL3032
Newman TJ.
Clinical investigators and the pharmaceutical industry (1st of 3 letters)
New England Journal of Medicine 2000 Aug 17;343(7):510-511
http://content.nejm.org/cgi/content/full/343/7/510
HSL3041
Miller P.
Is academic medicine for sale? (12th of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL7550
Bellin E.
Clinical investigators and the pharmaceutical industry.
N Engl J Med 2000 Aug 17;343(7):511
http://content.nejm.org/cgi/content/full/343/7/510
HSL7553
Dillon DC.
Is academic medicine for sale? (6th of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL7554
Firlik AD, Lowry DW.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17;343(7):509-10
http://content.nejm.org/cgi/content/full/343/7/508
HSL7555
Hagan BM.
Is academic medicine for sale? (11th of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL7556
Jagger J.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17;343(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL7557
Lebowitz J.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17;343(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL7558
Leong GB, Silva AJ.
Is academic medicine for sale? (5th of 13 letters)
New England Journal of Medicine 2000 Aug 17;343(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL2361
Costly benefits and the conspiracy of goodwill
2000 Aug 9
HSL3047
McCarthy , M .
Medical-education companies come under fire in USA
Lancet 2000 Aug 5;356:494
HSL7549
McCarthy M.
Medical-education companies come under fire in USA
Lancet 2000 Aug 5;356:494
HSL8543
Sellers JA.
The two faces of direct-to-consumer advertising.
Am J Health Syst Pharm 2000 Aug 1;57(15):1401
http://www.ajhp.org/cgi/reprint/57/15/1401
HSL8546
Thompson CA.
Medicare to use new wholesale drug prices, says Shalala
American Journal of Health System Pharmacy 2000 Aug 1;57:1384, 1386
HSL7547
Conflicts of interest (Relations between health professionals and industry)
Prescrire International 2000 Aug;9(48):126
HSL7548
Chepesiuk R, Perkin RL.
Who looks at drug advertising?
Canadian Family Physician 2000 Aug(46)
HSL8471
Carpenter D.
Bitter pills
Hospitals and Health Networks 2000 Aug;74:48-52
HSL3039
Montauk L.
Medical junk mail.
Lancet 2000 Jul 22;356(9226):344
HSL7546
Durrington PN, Chantler K.
Academia and industry.
Lancet 2000 Jul 22;356(9226):339
HSL2983
Wolfe S, Lurie P, Sasich L, Barbehenn E.
Information on thiazolidinediones (1st of 2 letters)
The Lancet 2000 Jul 15;356:254-5
HSL7545
Auwerx J.
Information on thiazolidinediones (2nd of 2 letters)
The Lancet 2000 Jul 15;356:255
HSL3014
Recker RR.
Disclosure of authors' conflicts of interest--a follow-up.
N Engl J Med 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL3030
Recker RR.
Disclosure of authors' conflicts of interest - A follow-up (2nd of 4 letters)
New England Journal of Medicine 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL3043
McMasters KM.
Disclosure of authors' conflicts of interest - A follow-up (1st of 4 letters)
New England Journal of Medicine 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL7543
Goldberg B.
Disclosure of authors' conflicts of interest--a follow-up.
N Engl J Med 2000 Jul 13;343(2):146-7
HSL7544
McMasters KM.
Disclosure of authors' conflicts of interest--a follow-up.
N Engl J Med 2000 Jul 13;343(2):146
HSL8542
Levy S.
Study finds strong consumer awareness of DTC Rx ads
Drug Topics 2000 Jul 3;144:47
HSL354
Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS.
A physician survey of the effect of drug sample availability on physicians' behavior.
J Gen Intern Med 2000 Jul;15(7):478-83
Nil
HSL8469
Brotman BA.
The price of pharmaceuticals given managed care health insurance membership.
Pharm Pract Manag Q 2000 Jul;20(2):16-9
HSL8547
Wechsler J.
Health plans and payers attack DTC advertising, seek objective information on medication value
Formulary 2000 Jul;35:616-617
HSL14025
Fuan L, Miniard PW, Barone MJ.
The Facilitating Influence of Consumer Knowledge on the Effectiveness of Daily Value Reference Information
Journal of the Academy of Marketing Science 2000 Jul;28(3):425-35
http://jam.sagepub.com/cgi/content/abstract/28/3/425
HSL3001
Rubin P.
The New England Journal of Medicine - To whom is it accountable?
2000 Jun 27
HSL2364
Seaman B.
The Pill and I: 40 Years On, the Relationship Remains Wary
The New York Times 2000 Jun 25
HSL2984
Wilmshurst P.
Academia and industry (1st of 2 letters)
The Lancet 2000 Jun 22;356:338-339
HSL3016
O'Hare N.
Pill pushers
Listener 2000 Jun 17:19-23
HSL8566
Texas fight over drug product selection ends
American Journal of Health System Pharmacy 2000 Jun 15;57:1117
HSL8577
Chisholm MA, Reinhardt BO, Vollenweider LJ, Kendrick BD, DiPiro JT.
Medication assistance programs for uninsured and indigent patients.
Am J Health Syst Pharm 2000 Jun 15;57(12):1131-6
http://www.ajhp.org/cgi/reprint/57/12/1131
HSL329
Tallon D, Chard J, Dieppe P.
Relation between agendas of the research community and the research consumer.
Lancet 2000 Jun 10;355(9220):2037-40
http://linkinghub.elsevier.com/retrieve/pii/S0140673600023515
HSL8516
Aitken M, Holt F.
Consumer choice or chaos?
Chemist and Druggist 2000 Jun 10;253:34, 36
HSL9593
Balasubramaniam T
Background Information on Fourteen FDA Approved HIV/AIDS Drugs
Washington, DC: Consumer Project on Technology; 2000 Jun 8
http://www.cptech.org/ip/health/aids/druginfo.html
HSL339
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB.
Coverage by the news media of the benefits and risks of medications.
N Engl J Med 2000 Jun 1;342(22):1645-50
http://content.nejm.org/cgi/content/full/342/22/1645
HSL355
Chard JA, Tallon D, Dieppe P.
Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint
Annals of the Rheumatic Diseases 2000 Jun;59:414-418
http://ard.bmjjournals.com/cgi/content/full/59/6/414
HSL2174
Mehta PN.
Drugmakers and continuing medical education.
Indian Pediatr 2000 Jun;37(6):626-30
HSL4166
Researched Medicines Industry (RMI).
Direct to consumer advertising can enhance public health. The case for direct-to-consumer prescription medicine advertising.
Wellington NZ: Researched Medicines Industry (RMI).; 2000 Jun
HSL5089
D'Arcy PF, Hadden DR.
Are drug proprietary names necessary?
Adverse Drug React Toxicol Rev 2000 Jun;19(2):117-21
HSL1976
Wazana A.
Gifts to physicians from the pharmaceutical industry
JAMA 2000 May 24;283(20):2655-8
HSL2988
Wazana A.
Gifts to physicians from the pharmaceutical industry [1st of 2 replies]
JAMA 2000 May 24-31;283(20):2675
HSL3044
McKinney WP.
Gifts to physicians from the pharmaceutical industry [4th of 4 letters]
JAMA 2000 May 24-31;283(20):2656-7
HSL7538
Edwards DA.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31;283(20):2656
HSL7539
Howard SM.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31;283(20):2655-6
HSL7540
McKinney WP, Rich EC.
Gifts to physicians from the pharmaceutical industry.
JAMA 2000 May 24-31;283(20):2656-7
HSL7541
Vollman J.
Gifts to physicians from the pharmaceutical industry [3rd of 4 letters]
JAMA 2000 May 24-31;283(20):2656
HSL356
Bodenheimer T.
Uneasy alliance--clinical investigators and the pharmaceutical industry.
N Engl J Med 2000 May 18;342(20):1539-44
http://content.nejm.org/cgi/content/extract/342/20/1539
HSL361
Angell M.
Is academic medicine for sale?
N Engl J Med 2000 May 18;342(20):1516-8
http://content.nejm.org/cgi/content/extract/342/20/1516
HSL9595
Office of the Chairman
The Benefits of Medical Research and the Role of the NIH
Washington, DC: US Senate; 2000 May 17
http://hsc.utoledo.edu/research/nih_research_benefits.pdf
HSL1032
Irwig LM, Loy CT, Chapman S, Glasziou PP, Mansfield PR, Salkeld GP, Walton MM.
!nform test kits distributed with the MJA.
Med J Aust 2000 May 15;172(10):518-9
HSL8549
Starr CH.
When drug names spell trouble
Drug Topics 2000 May 15;144:49-50, 53-54, 57-58
HSL7537
MacKay P.
Pharmaceutical advertising - as seen on TV
New Zealand Association Newsletter 2000 May 12:1-2
HSL2987
Weatherall D.
Academia and industry: increasingly uneasy bedfellows.
Lancet 2000 May 6;355(9215):1574
http://linkinghub.elsevier.com/retrieve/pii/S014067360002211X
HSL2656
Sackett DL.
Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle.
CMAJ 2000 May 2;162(9):1311-4
http://www.cmaj.ca/cgi/content/full/162/9/1311
HSL8579
Swartwood DE.
Ethics and managed care formularies.
Am J Health Syst Pharm 2000 May 1;57(9):851
http://www.ajhp.org/
HSL8584
McAllister JC.
Fortresses and formularies: response 3
American Journal of Health System Pharmacy 2000 May 1;57:859-860
HSL7536
Kollek D.
How advertisements have changed
Canadian Family Physician 2000 May;46:1025-1026
HSL8453
Cooper W.
Drug wars, episode two: health plans strike back
Pharmaceutical Executive 2000 May:110, 112, 114
HSL8458
Wechsler J.
Congressional concerns
Pharmaceutical Executive 2000 May;20:22, 24, 26, 28
HSL8483
Smeaton J.
To market, to market
Australian Journal of Pharmacy 2000 May;81:470-471
HSL8563
Gebhart F.
They shoot! They score! Rx scoreboard
Drug Topics 2000 Apr 3;144:31-32, 35-36, 39
HSL5843
Medical Research Council
A framework for development and evaluation of RCTs for complex interventions to improve health
: Medical Research Council; 2000 Apr 1
http://www.mrc.ac.uk/prn/pdf-mrc_cpr.pdf
HSL2997
Sarmiento A.
Medicine and industry: The payer, the piper, and the tune
Annales CRMCC 2000 Apr;33(3):144-149
HSL4169
Bell RA, Kravitz RL, Wilkes MS.
Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals.
J Fam Pract 2000 Apr;49(4):329-35
http://www.jfponline.com/Pages.asp?AID=2488
HSL7535
Barros JA.
[(Mis)information on drugs: the double standard practiced by pharmaceutical companies]
Cad Saude Publica. 2000 Apr-Jun;16(2):421-7
Link to source with long URL
HSL2994
Sharp D.
Drug industry code proposed on "ghost" writing
Lancet 2000 Mar 25;355:1084
HSL8557
Prescriptions benefits for America's elderly
Lancet 2000 Mar 25;355:1027
HSL8562
Conlan MF.
Consumers speak out
Drug Topics 2000 Mar 20;144:71-72, 74, 77-78, 81
HSL288
Willman D.
Fears Grow Over Delay in Removing Rezulin Health: Five FDA physicians say the lives of diabetes patients are at stake. Company's conduct in development of the drug also comes under fire.
The Los Angeles Times 2000 Mar 10
HSL7532
Armstrong K, Asch DA.
Direct sale of sildenafil (Viagra) to consumers over the Internet (3rd of 3 letters)
New England Journal of Medicine 2000 Mar 9;342(10):742
HSL7533
deKieffer DE.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 2000 Mar 9;342(10):742
HSL7534
Henney JE, Shuren JE.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 2000 Mar 9;342(10):740,
HSL12242
Miller D, Dinan W.
The Rise of the PR Industry in Britain, 1979-98
European Journal of Communication 2000 Mar 1;15(1):5-35
http://ejc.sagepub.com/cgi/content/abstract/15/1/5
HSL3015
Press E, Washburn J.
The kept university
Atlantic Monthly 2000 Mar:39-42, 44-52, 54
www.theatlantic.com/issues/2000/03/press.htm
HSL7526
Wilkes MS, Bell RA, Kravitz RL.
Direct-to-consumer prescription drug advertising: trends, impact, and implications.
Health Aff (Millwood) 2000 Mar-Apr;19(2):110-28
http://content.healthaffairs.org/cgi/reprint/19/2/110
HSL7529
Lexchin J.
Plus ça change.
Canadian Family Physician 2000 Mar;46:532-6
HSL7530
Lexchin J.
Re: the promotion of Augmentin (amoxycillin/clavulanate)
2000 Mar
HSL8525
Edlin M.
Health plans rein in formulary costs
Managed Healthcare 2000 Mar;10:30-32, 48
HSL347
Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, Stevens R.
Systematic reviews and meta-analyses on treatment of asthma: critical evaluation.
BMJ 2000 Feb 26;320(7234):537-40
http://bmj.bmjjournals.com/cgi/content/full/320/7234/537
HSL7528
Angell M, Utiger RD, Wood AJ.
Disclosure of authors' conflicts of interest: a follow-up.
N Engl J Med 2000 Feb 24;342(8):586-7
HSL9594
Consumer Project on Technology
Additional notes on government role in the development of HIV/AIDS drugs
Washington, DC: Consumer Project on Technology; 2000 Feb 23
http://www.cptech.org/ip/health/aids/gov-role.html
HSL286
Willman D.
Key Physician Urges Rezulin Be Withdrawn Medicine: FDA official says 'preventable liver failure' may occur if diabetes pill remains on market. The number of injuries and deaths linked to drug rises.
The Los Angeles Times 2000 Feb 19
HSL2450
Hemminki E, McPherson K.
Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.
Lancet 2000 Feb 12;355(9203):566-9
http://linkinghub.elsevier.com/retrieve/pii/S0140673699034327
HSL2176
Damur C, Steurer J.
[Do physicians interpret therapy outcome differently than students?]
Schweiz Med Wochenschr 2000 Feb 12;130(6):171-6
HSL8575
Levy S.
First DTC drug ads of 2000 promote a wide assortment
Drug Topics 2000 Feb 7;144:120, 122
HSL8576
Chi J.
Drug budget spiraling out of control? Here's how to rein in your costs
Drug Topics 2000 Feb 7;144:64
HSL8528
Smeaton J.
Moving pictures
Australian Journal of Pharmacy 2000 Feb;81:128-129
HSL7527
Hailey D.
Scientific harassment by pharmaceutical companies: time to stop.
CMAJ 2000 Jan 25;162(2):212-3
Link to source with long URL
HSL2517
Wazana A.
Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA 2000 Jan 19;283(3):373-80
http://jama.ama-assn.org/cgi/content/full/283/3/373
HSL2989
Tenery RM Jr.
Interactions between physicians and the health care technology industry.
JAMA 2000 Jan 19;283(3):391-3
http://jama.ama-assn.org/cgi/content/full/283/3/391
HSL8588
Gebhart F.
Flush with victory, compounding pharmacists see demand soar
Drug Topics 2000 Jan 17;144:28, 31
HSL8539
Reissner D.
Pharmacy on the Net: is it legal?
Chemist and Druggist 2000 Jan 15;253:20
HSL8581
Levy S.
Marketing switch
Drug Topics 2000 Jan 3;144:36
HSL343
Lovdahl U, Riska E.
The construction of gender and mental health in Nordic psychotropic-drug advertising.
Int J Health Serv 2000;30(2):387-406
Nil
HSL362
Angell M.
The pharmaceutical industry--to whom is it accountable
N Engl J Med 2000;342:1902-1904
http://content.nejm.org/cgi/content/extract/342/25/1902
HSL3050
Maestri E, Furlani G, Suzzi F, Campomori A, Formoso G, Magrini N.
So much time for so little: Italy's pharmaceutical industry and doctors' information needs.
BMJ 2000 Jan 1;320(7226):55-6
http://bmj.com/cgi/content/full/320/7226/55
HSL2438
Robinson P, Heywood P.
What do GPs need to know? The use of knowledge in general practice consultations.
Br J Gen Pract 2000 Jan;50(450):56-9
Link to source with long URL
HSL8544
Smith DL.
Don't forget about us after the initial DTC ad
Pharmaceutical Executive 2000 Jan;20:113
HSL8545
West D.
Dialing for DTC: operation 1-800-call center gets the scoop
Pharmaceutical Executive 2000 Jan;20:98-100, 102, 104, 106
HSL2406
Sutherland M, Sylvester AK.
Advertising and the Mind of the Consumer 2nd Ed: What works, what doesn't, and why.
Sydney: Allen & Unwin; 2000
Link to source with long URL
HSL349
Guldal D, Semin S.
The influences of drug companies' advertising programs on physicians
Int J Health Serv 2000;30(3):585-95
Nil
HSL1766
Cialdini RB.
Influence: Science and Practice 4th Edn
New York: Allyn & Bacon; 2000
http://www.ablongman.com/catalog/academic/product/0,1144,0321011473,00.html
HSL2390
Braithwaite J, Drahos P.
Global business regulation.
Cambridge: Cambridge University Press; 2000
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521784999
HSL2164
Pearson S, Smith AJ, Rolfe IE, Moulds RF, Shenfield GM.
Intern Prescribing for Common Clinical Conditions.
Adv Health Sci Educ Theory Pract 2000;5(2):141-150
Link to source with long URL
HSL2172
Candy PC.
Preventing "information overdose": developing information-literate practitioners.
J Contin Educ Health Prof 2000 Fal;20(4):228-37
HSL2609
Roughead L, Semple S, Vitry A.
The Value of Pharmacist Professional Services in the Community: A systematic review of the literature 1990-2002
2000
HSL2694
Freemantle , N. JOHNSSON, R. , Dennis J., Kennedy , A. MARCHMENT, M
Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/ industry intervention to influence prescribing practice.
British Journal of Clinical Pharmacology 2000;49:174-179
Nil
HSL2985
Wilkes M.
Direct-to-consumer prescription drug advertising: trends, impact, and implications
Health Affairs 2000;19(2):110-128
HSL2990
Sweet M.
Medicines and the media: a journalist's view
Australian Prescriber 2000;23(4):70-1
http://www.australianprescriber.com
HSL3003
Roughead L, Gilbert A.
Medicines and the media
Australian Prescriber 2000;23(6):115
http://www.australianprescriber.com
HSL3038
Morgan S, Barer M, Evans R.
Buying science, selling drugs
Health Matters 2000;43:12-13
HSL5884
Kohn LT, Corrigan JM, Donaldson MS, .
To Err Is Human: Building a Safer Health System
Washington, DC: National Academies Press; 2000
HSL5970
Baron J.
Thinking and Deciding 3rd edn
Cambridge: Cambridge University Press; 2000
HSL6780
Sparrow MK.
The regulatory craft: Controlling risks, solving problems and managing compliance
Washington: The Brookings Institution; 2000
HSL7518
Ala-fossi N, Vilhunen S, Lilja J, Enlund H.
Promoting antidepressants to physicians in Finnish direct mail and journal advertisements
Journal of Social and Administrative Pharmacy 2000;17:9-14
HSL7519
Day R.
How to make the most of a visit from a pharmaceutical company representative
Australian Prescriber 2000;23(5):97-99
http://www.australianprescriber.com
HSL7520
Dennis RJ.
Drug promotion: Does the right hand know what the left is doing?
Pharmacoepidemiology and Drug Safety 2000;9:291-292
HSL7522
Kopp SW, Bang HK.
Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications
Health Mark Q 2000;17(3):39-56
HSL7523
Lexchin J.
Double standards: Double jeopardy
Pharmacoepidemiology and Drug Safety 2000;9:289-290
HSL7524
Lovdahl U, Riska E.
The construction of gender and mental health in Nordic psychotropic-drug advertising.
Int J Health Serv 2000;30(2):387-406
HSL7531
Duncan B, Miller S, Sparks J.
Exposing the mythmakers
Family Therapy Networker 2000;24(2):24-33, 52-53
http://www.angelfire.com/co2/counseling/drugs-depression.html
HSL7542
Lalonde A.
Selling, or selling out? [response]
Journal of the Society of Obstetricians and Gynaecologists of Canada 2000;22(7):497
HSL7551
Bodenheimer T.
Clinical investigators and the pharmaceutical industry (3rd of 3 letters)
New England Journal of Medicine 2000;343(7):511
http://content.nejm.org/cgi/content/full/343/7/510
HSL7552
Diamond C.
Is academic medicine for sale? (9th of 13 letters)
New England Journal of Medicine 2000;343(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL7871
Smith BL, Korn D.
Is there a crisis of accountability in the American research university?
Minerva 2000;38(2):129-45
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed
HSL8480
Soller RW.
OTCs 2000: achievements and challenges
Drug Information Journal 2000;34(3):693-701
HSL8481
Morris LA, Pines WL.
Regulation of pharmaceutical promotion in the twenty-first century
Drug Information Journal 2000;34(3):861-873
HSL8482
Rosati S.
Community pharmacy and SB393
California Pharmacist 2000;47(2):20
HSL8517
Kizer JR, Kimmel SE.
Calcium channel blocker controversy: historical perspective and important lessons for future pharmacotherapies-International Society of Pharmacoepidemiology hot topic
Pharmacoepidemiology and Drug Safety 2000;9(1):25-36
HSL8518
Nolan A.
Pharmaceutical advertising in clinical software
Australian Prescriber 2000;23(3):52-53, 67
HSL8519
Letendre W, Jackson R.
Marketing your prescription compounding practice. Part 3
International Journal of Pharmaceutical Compounding 2000;4(3):199-202
HSL8540
Desselle SP, Aparasu R.
Attitudinal dimensions that determine pharmacists' decisions to support DTCA of prescription medication
Drug Information Journal 2000;34(1):103-114
HSL8548
Breu J.
Higher utilization, new products driving prescription spending
Drug Topics 2000;144
HSL12246
Mills F.
Patient groups and the Global Pharmaceutical Industry
London: URCH publishing; 2000
Link to source with long URL
HSL13996
Brucks M, Zeithaml VA, Naylor G.
Price and Brand Name As Indicators of Quality Dimensions for Consumer Durables
Journal of the Academy of Marketing Science 2000 Summer;28(3):359-374
http://jam.sagepub.com/cgi/content/abstract/28/3/359
HSL14008
Gigerenzer G, Todd PM, and ABC Research Group
Simple Heuristics That Make Us Smart
: Oxford University Press; 2000
http://www.oup.com/uk/catalogue/?ci=9780195143812#desc